A clinicopathological study of breast cancer was carried out by Xu et al., which immunohistochemically analyzed S100A14 protein expression, and which reported that patient prognosis was poorer in cases in which S100A14 and HER2 were co-expressed compared to cases that did not express either protein. Here, S100A14 is linked to breast carcinoma.